| 1 |
2023 |
Feng Wen, Tianhai Lin, Peng Zhang, Yali Shen. 2023;
https://doi.org/10.21203/rs.3.rs-2424409/v1 |
| 2 |
2025 |
Gaurisha alias Resha Ramnath Naik, Amrita Arup Roy, Namdev Dhas, Srinivas Mutalik, Ruchi Tiwari, Gaurav Tiwari, Ritu Kudarha. 2025; 113.
https://doi.org/10.1016/B978-0-443-29168-5.00021-0 |
| 3 |
2022 |
Erin F. Cobain, Daniel F. Hayes. Expanding the reach of HER2-targeted therapies: transformation of an historical paradigm, Journal of Clinical Investigation. 2022; 132: e166384.
https://doi.org/10.1172/JCI166384 |
| 4 |
2023 |
Christian Werner Wichmann, Ingrid Julienne Georgette Burvenich, Nancy Guo, Angela Rigopoulos, Alexander McDonald, Diana Cao, Graeme Joseph O'Keefe, Sylvia Jie Gong, Hui Kong Gan, Fiona Elizabeth Scott, Nabendu Pore, Steven Coats, Andrew Mark Scott. Preclinical radiolabeling, in vivo biodistribution and positron emission tomography of a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2, Nuclear Medicine and Biology. 2023; 122-123: 108366108366.
https://doi.org/10.1016/j.nucmedbio.2023.108366 |
| 5 |
2025 |
Takhellambam Malemnganba, Anurag Kumar Pandey, Amit Mishra, Sanjana Mehrotra, Vijay Kumar Prajapati. 2025; 144: 259.
https://doi.org/10.1016/bs.apcsb.2024.10.016 |
| 6 |
2023 |
Rafael F. A. Gomes, Bruno M. F. Gonçalves, Késsia H. S. Andrade, Bárbara B. Sousa, Nuno Maulide, Gonçalo J. L. Bernardes, Carlos A. M. Afonso. Unlocking the Potential of Bio‐Based Nitrogen‐Rich Furanic Platforms as Biomass Synthons, Angewandte Chemie. 2023; 135: e202304449.
https://doi.org/10.1002/ange.202304449 |
| 7 |
2024 |
Giacomo Domenici, Nuno F. Lopes, Gonçalo Trindade, Isabella Ramella Gal, Joan Miret Minard, Sofia P. Rebelo, Catarina Freitas, Nádia Duarte, Catarina Brito. Assessing Novel Antibody‐Based Therapies in Reconstructive 3D Cell Models of the Tumor Microenvironment, Advanced Biology. 2024; 8: 2400431.
https://doi.org/10.1002/adbi.202400431 |
| 8 |
2023 |
Ritwik Maiti, Bhumika Patel, Nrupesh Patel, Mehul Patel, Alkesh Patel, Nirav Dhanesha. Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities, Archives of Pharmacal Research. 2023; 46: 361.
https://doi.org/10.1007/s12272-023-01447-0 |
| 9 |
2023 |
Rafael F. A. Gomes, Bruno M. F. Gonçalves, Késsia H. S. Andrade, Bárbara B. Sousa, Nuno Maulide, Gonçalo J. L. Bernardes, Carlos A. M. Afonso. Unlocking the Potential of Bio‐Based Nitrogen‐Rich Furanic Platforms as Biomass Synthons, Angewandte Chemie International Edition. 2023; 62: e202304449.
https://doi.org/10.1002/anie.202304449 |
| 10 |
2024 |
Feng Wen, Tianhai Lin, Peng Zhang, Yali Shen. RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03), Frontiers in Oncology. 2024; 13: 1233196.
https://doi.org/10.3389/fonc.2023.1233196 |
| 11 |
2025 |
Tiantian Zhang, Shuo He, Lu Tao, Mengting Shi, Yue Wu, Yuanyuan Guo, Rui Wang. Efficacy and safety of RC48 in combination with PD-1 inhibitors for the treatment of locally advanced or metastatic urothelial carcinoma: a single-center, real-world study, Discover Oncology. 2025; 16: 558.
https://doi.org/10.1007/s12672-025-02362-0 |
| 12 |
2025 |
Fatima Akram, Amna Murrawat Ali, Muhammad Tayyab Akhtar, Taseer Fatima, Ifrah Shabbir, Ikram ul Haq. The journey of antibody-drug conjugates for revolutionizing cancer therapy: A review, Bioorganic & Medicinal Chemistry. 2025; 117: 118010118010.
https://doi.org/10.1016/j.bmc.2024.118010 |
| 13 |
2023 |
Ivana Jarak, Ana Isabel Santos, Ana Helena Pinto, Cátia Domingues, Inês Silva, Raquel Melo, Francisco Veiga, Ana Figueiras. Colorectal cancer cell exosome and cytoplasmic membrane for homotypic delivery of therapeutic molecules, International Journal of Pharmaceutics. 2023; 646: 123456123456.
https://doi.org/10.1016/j.ijpharm.2023.123456 |
| 14 |
2024 |
Xiehui Chen, Changchun Zeng. Pioneering the Way: The Revolutionary Potential of Antibody–Drug Conjugates in NSCLC, Current Treatment Options in Oncology. 2024; 25: 556.
https://doi.org/10.1007/s11864-024-01196-2 |
| 15 |
2024 |
Elisabete Cruz Da Silva, Charlène D’Ancona, Hélène Justiniano, Valérie Calco, Dilara Sensoy, Pascal Villa, Romain Vauchelles, Maxime Lehmann, Laurence Choulier. 2024;
https://doi.org/10.1101/2024.10.22.617611 |
| 16 |
2025 |
Naveen Kumar, Shishu Kant Suman, Mohini Guleria, Soumi Kolay, Jeyachitra Amirdhanayagam, Avik Chakraborty, Sutapa Rakshit, Archana Mukherjee, Tapas Das. Chlorambucil Conjugation Enhances the Potency of Rituximab: Synthesis and Evaluation of the Novel [177Lu]Lu-Labeled Rituximab-Chlorambucil Conjugate toward Therapy of Non-Hodgkin’s Lymphoma, Journal of Medicinal Chemistry. 2025; 68: 1365.
https://doi.org/10.1021/acs.jmedchem.4c01954 |
| 17 |
2022 |
Marilia Barreca, Noémie Lang, Chiara Tarantelli, Filippo Spriano, Paola Barraja, Francesco Bertoni. Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences, Exploration of Targeted Anti-tumor Therapy. 2022; 763.
https://doi.org/10.37349/etat.2022.00112 |
